[go: up one dir, main page]

AU2012903365A0 - Compounds for the treatment of mTOR pathway related diseases - Google Patents

Compounds for the treatment of mTOR pathway related diseases

Info

Publication number
AU2012903365A0
AU2012903365A0 AU2012903365A AU2012903365A AU2012903365A0 AU 2012903365 A0 AU2012903365 A0 AU 2012903365A0 AU 2012903365 A AU2012903365 A AU 2012903365A AU 2012903365 A AU2012903365 A AU 2012903365A AU 2012903365 A0 AU2012903365 A0 AU 2012903365A0
Authority
AU
Australia
Prior art keywords
compounds
treatment
related diseases
mtor pathway
pathway related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012903365A
Inventor
Roger Aston
David L. Morris
Mohammad Hossein Pourgholami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewSouth Innovations Pty Ltd
Pitney Pharmaceuticals Pty Ltd
Original Assignee
NewSouth Innovations Pty Ltd
Pitney Pharmaceuticals Pty Ltd
Filing date
Publication date
Application filed by NewSouth Innovations Pty Ltd, Pitney Pharmaceuticals Pty Ltd filed Critical NewSouth Innovations Pty Ltd
Publication of AU2012903365A0 publication Critical patent/AU2012903365A0/en
Priority to NZ729555A priority Critical patent/NZ729555A/en
Priority to US14/420,081 priority patent/US9790176B2/en
Priority to PCT/AU2013/000859 priority patent/WO2014022879A1/en
Priority to CN201510883323.4A priority patent/CN105496999A/en
Priority to CN201380051602.3A priority patent/CN104837812B/en
Priority to ES13827913T priority patent/ES2627099T3/en
Priority to PL13827913T priority patent/PL2880014T3/en
Priority to NZ631523A priority patent/NZ631523A/en
Priority to JP2015525692A priority patent/JP6441219B2/en
Priority to EP17162895.1A priority patent/EP3202397B1/en
Priority to ES17162895T priority patent/ES2757598T3/en
Priority to HK15106070.3A priority patent/HK1205502B/en
Priority to KR1020157003924A priority patent/KR102124392B1/en
Priority to AU2013302209A priority patent/AU2013302209B2/en
Priority to CA2881325A priority patent/CA2881325C/en
Priority to EP13827913.8A priority patent/EP2880014B1/en
Priority to ZA2015/01390A priority patent/ZA201501390B/en
Priority to AU2016234924A priority patent/AU2016234924B2/en
Priority to US15/613,635 priority patent/US10053422B2/en
Priority to JP2018003249A priority patent/JP6509386B2/en
Abandoned legal-status Critical Current

Links

AU2012903365A 2012-08-06 2012-08-06 Compounds for the treatment of mTOR pathway related diseases Abandoned AU2012903365A0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
EP13827913.8A EP2880014B1 (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
JP2015525692A JP6441219B2 (en) 2012-08-06 2013-08-05 Compounds for treating mTOR pathway related diseases
HK15106070.3A HK1205502B (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
PCT/AU2013/000859 WO2014022879A1 (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
CN201510883323.4A CN105496999A (en) 2012-08-06 2013-08-05 Compounds for the treatment of mTOR pathway related diseases
CN201380051602.3A CN104837812B (en) 2012-08-06 2013-08-05 Compounds for treating diseases associated with mTOR pathway
ES13827913T ES2627099T3 (en) 2012-08-06 2013-08-05 Compounds for the treatment of diseases related to the mTOR pathway
PL13827913T PL2880014T3 (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
NZ631523A NZ631523A (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
NZ729555A NZ729555A (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
EP17162895.1A EP3202397B1 (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
ES17162895T ES2757598T3 (en) 2012-08-06 2013-08-05 Compounds for the treatment of diseases related to the mTOR pathway
US14/420,081 US9790176B2 (en) 2012-08-06 2013-08-05 Compounds for the treatment of mTOR pathway related diseases
KR1020157003924A KR102124392B1 (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
AU2013302209A AU2013302209B2 (en) 2012-08-06 2013-08-05 Compounds for the treatment of mTOR pathway related diseases
CA2881325A CA2881325C (en) 2012-08-06 2013-08-05 Compounds for the treatment of mtor pathway related diseases
ZA2015/01390A ZA201501390B (en) 2012-08-06 2015-03-02 Compounds for the treatment of mtor pathway related diseases
AU2016234924A AU2016234924B2 (en) 2012-08-06 2016-09-28 Compounds for the treatment of mTOR pathway related diseases
US15/613,635 US10053422B2 (en) 2012-08-06 2017-06-05 Compounds for the treatment of mTOR pathway related diseases
JP2018003249A JP6509386B2 (en) 2012-08-06 2018-01-12 Compounds for treating mTOR pathway related diseases

Publications (1)

Publication Number Publication Date
AU2012903365A0 true AU2012903365A0 (en) 2012-08-23

Family

ID=

Similar Documents

Publication Publication Date Title
ZA201402424B (en) 1- arylcarbonyl -4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
ZA201501390B (en) Compounds for the treatment of mtor pathway related diseases
EP2673286A1 (en) Therapeutic compounds
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
ZA201403795B (en) Formulations for the treatment of diabetes
PT2925757T (en) Compounds and compositions for the treatment of parasitic diseases
WO2011140517A9 (en) Methods for treating diseases of the lung
EP2994460A4 (en) Compounds for treatment of angiogenesis-mediated diseases
EP2617445B8 (en) System for medical treatment
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
PL395469A1 (en) Indolamines derivatives for the treatment of diseases of the central nervous system
AU2012903365A0 (en) Compounds for the treatment of mTOR pathway related diseases
HK40043513B (en) Interval therapy for the treatment of eye diseases
HK1193343A (en) Methods for treating diseases of the retina
HK1196953A1 (en) Formulations for the treatment of diabetes
HK1185284A (en) Compounds for the treatment/prevention of ocular inflammatory diseases
HK1188955A (en) Methods for treating diseases of the retina
HK1197236B (en) Compounds for the treatment of addiction
HK1182092A (en) Arylosulfonamides for the treatment of cns diseases
GB201009094D0 (en) Compounds for the treatment of closridium difficile-associated disease
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
GB201106981D0 (en) Compounds for the treatment of clostridium difficle-associated disease
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
HK1187328A (en) Methods for treating neurodegenerative diseases